Humanization of the Shark V Single Domain Antibody Using CDR Grafting.

Curr Protoc

Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.

Published: January 2023

The variable domain of the new antigen receptor (V ) of shark single domain antibodies is evolutionarily distant from the variable regions (V ) of mammalian immunoglobulins, yet it still has complementarity-determining regions (CDRs) that are involved in antigen recognition, therefore making it possible to humanize by grafting these CDRs to the framework of human V homologs. Here, we show the V CDR based on an analysis of currently available V -antigen structure complexes in the global Protein Data Bank archive of 3D structure data, and describe the detailed protocol to humanize V by CDR grafting, using B6 (an anti-Pseudomonas exotoxin V ), the most common type (Type II) of shark V s, as an example. Ongoing efforts will further optimize the protocol for moving shark V s to the clinic for treating cancer and other human diseases. Published 2023. This article is a U.S. Government work and is in the public domain in the USA. Basic Protocol: Humanize shark V sequence by CDR grafting Support Protocol 1: V structure prediction and comparison Support Protocol 2: Measure binding kinetics of humanized V using bio-layer interferometry (BLI).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813873PMC
http://dx.doi.org/10.1002/cpz1.630DOI Listing

Publication Analysis

Top Keywords

cdr grafting
12
shark single
8
single domain
8
protocol humanize
8
support protocol
8
protocol
5
humanization shark
4
domain
4
domain antibody
4
cdr
4

Similar Publications

This study aims to evaluate the management of oro-antral communications (OAC) and fistulas (OAF), focusing on treatment strategies based on defect size, epithelialization, and the presence of sinus infections, while exploring both traditional and emerging techniques. The systematic review was conducted following the PRISMA guidelines and registered on PROSPERO (CDR ID 623251). Using targeted keywords, articles in English published within the last 10 years were analyzed from databases such as PubMed, WoS and Scopus, selecting only clinical studies on human patients.

View Article and Find Full Text PDF

The application of antibody therapeutics is promising in the field of immunotherapy. While, heterologization should be done in most cases before applying the therapeutic antibodies into bodies, e.g.

View Article and Find Full Text PDF

Engineering and characterization of Hu3A4: A novel humanized antibody with potential as a therapeutic agent against myeloid lineage leukemias.

Neoplasia

January 2025

Division of Hematology-Oncology, Pediatric Hematology-Oncology Center, Zhejiang Provincial Research Center for Childhood Leukemia New Diagnostic and Therapeutic Techniques, Children's Hospital, Zhejiang University School of Medicine, National Clinical Medical Research Center for Child Health, #57 Zhugan Road, Yan-an Street, Hangzhou 310006, China. Electronic address:

Leukemia stem cells (LSCs) play a critical role in the initiation, recurrence, and resistance to treatment of leukemia. Eradicating LSCs is crucial for the complete elimination of the disease. CD45RA is identified as an important marker for LSC subsets in acute myeloid leukemia (AML), providing a strategic target for therapy.

View Article and Find Full Text PDF

Most of currently available sandwich-type enzyme-linked immunosorbent assays (ELISA) require the use of full-length animal-derived antibodies which poses welfare criticisms and are often expensive to produce. There is therefore a strong demand for the development of more affordable and animal-free methods to produce antibodies for sandwich ELISA assay. To address these issues, we propose here the development of a new technology based on two complementary rabbit single-chain variable fragments (scFvs) and an Ig-binding domain of protein L (PpL1) fused to a polystyrene-binding peptide (PS-tag) that can be recombinantly produced in bacteria.

View Article and Find Full Text PDF

Chimeric antigen receptor (CAR) T-cell therapy fails to achieve durable responses in over 60% of relapsed/refractory (R/R) large B-cell lymphoma (LBCL) patients in the third or later line setting. After CAR-T failure, survival outcomes are heterogeneous and a prognostic model in this patient population is lacking. A training cohort of 216 patients with progressive disease (PD) after CAR-T from 12 Spanish centers was used to develop the Post-CAR Prognostic Index (PC-PI); primary endpoint was overall survival (OS) from CAR-T progression.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!